SCHEMBL467798

SCHEMBL467798

COC(=O)CN(C)C1CCc2ccc(Nc3nc(N)nn3-c3cc4c(nn3)-c3ccccc3CCC4)cc2CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 12/20 0.51
AURKA O14965 1/20 0.51
EGFR P00533 1/20 0.51
RET P07949 1/20 0.51
MET P08581 1/20 0.51
KIT P10721 1/20 0.51
SRC P12931 1/20 0.51
PDGFRA P16234 1/20 0.51
KDR P35968 1/20 0.51
FLT3 P36888 1/20 0.51
TYRO3 Q06418 1/20 0.51
DDR1 Q08345 1/20 0.51
MERTK Q12866 1/20 0.51
AURKB Q96GD4 1/20 0.51
ALK Q9UM73 1/20 0.51
JAK2 O60674 2/20 0.33
JAK3 P52333 2/20 0.33
PTK2 Q05397 2/20 0.33
P2RX3 P56373 2/20 0.33
DHODH Q02127 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL467847 0.89 AXL (0.67) AXLAURKAEGFRRETMET
SCHEMBL30121668 0.89 AXL (0.67) AXLAURKAEGFRRETMET
SCHEMBL467451 0.86 AXL (0.56) AXLAURKAEGFRRETMET
SCHEMBL467927 0.85 AXL (0.60) AXLAURKAEGFRRETMET
SCHEMBL467806 0.82 AXL (0.59) AXLAURKAEGFRRETMET
SCHEMBL30090804 0.82 AXL (0.68) AXLAURKAEGFRRETMET
SCHEMBL467735 0.82 AXL (0.68) AXLAURKAEGFRRETMET
SCHEMBL2056491 0.81 AXL (0.51) AXLAURKAEGFRRETMET
SCHEMBL30090801 0.81 AXL (0.51) AXLAURKAEGFRRETMET
SCHEMBL467829 0.81 AXL (0.57) AXLAURKAEGFRRETMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2387395-A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER Rigel Pharmaceuticals, Inc. (US) 2011-11-23 EP disclosed
US-8040491-B2 Exposure method, substrate stage, exposure apparatus, and device manufacturing method NIKON CORPORATION (JP) 2011-10-18 US disclosed
WO-2010083465-A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER RIGEL PHARMACEUTICALS, INC. (US) 2010-07-22 WO disclosed